Transitional B cell cytokines predict renal allograft outcomes

Area of Science:

• Immunology
• Transplantation immunology
• Biomarker discovery

Background:

• Early detection of renal allograft rejection is crucial for timely intervention and improved patient outcomes.
• Current biomarkers lack the sensitivity to predict both early and late rejection events.
• Identifying reliable immunological markers is essential for guiding preemptive therapeutic strategies.

Purpose of the Study:

• To evaluate the ratio of interleukin-10 (IL-10) to tumor necrosis factor-α (TNFα) produced by transitional-1 B cells (T1B) as a predictive biomarker for renal allograft rejection.
• To assess the biomarker's ability to predict clinical and subclinical rejection, subsequent graft outcomes, and the potential for preemptive therapy.

Main Methods:

• Prospective analysis of the T1B IL-10/TNFα ratio in training, internal validation, and external validation cohorts of kidney transplant recipients.
• Correlation of the biomarker ratio with the incidence of early and late clinical and subclinical allograft rejection within the first year post-transplant.
• Assessment of the biomarker's association with renal function and long-term graft survival (5 years).
• In vitro studies investigating the effect of anti-TNFα treatment on T1B cell function.

Main Results:

• The T1B IL-10/TNFα ratio at 3 months post-transplant significantly predicted both early and late renal allograft rejection in all validation sets.
• High-risk patients identified by the biomarker had a substantially higher incidence of rejection and poorer 5-year graft survival.
• The biomarker demonstrated a lead time of approximately 8 months for predicting late rejection events.
• In vitro anti-TNFα treatment modulated the T1B IL-10/TNFα ratio, restored regulatory function, and inhibited plasmablast differentiation.

Conclusions:

• The T1B IL-10/TNFα ratio is a validated and robust predictive biomarker for renal allograft rejection and long-term outcomes.
• This biomarker facilitates the identification of high-risk patients who may benefit from preemptive therapeutic interventions.
• Targeting TNF blockade presents a promising therapeutic strategy for improving renal allograft survival based on this biomarker.